NCT01187550View on ClinicalTrials.gov

Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen®

PHASE4CompletedINTERVENTIONAL

Enrollment

214

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

April 30, 2009

Conditions

Dwarfism, Pituitary

Interventions

DRUG

Recombinant human growth hormone (r-hGH)

Recombinant human growth hormone (r-hGH) administered at dose of 0.033 milligram/kilogram (mg/kg) body weight (0.1 International Unit \[IU\]/kg body weight) per day by subcutaneous injection.

All Listed Sponsors

collaborator

Merck Serono Co., Ltd., China

INDUSTRY

lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT01187550 - Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen® | Biotech Hunter | Biotech Hunter